EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease

Cathy Burton, Pamela Allen, Alex F Herrera iD

American Society of Clinical Oncology Educational Book · 2024

DOI: 10.1200/edbk_433502 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024. Verfasst von Cathy Burton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, St James's University Hospital, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 107 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination chemotherapy with or without radiation has served as the primary therapeutic option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of patients with early- and advanced-stage cHL. Patients with relapsed/refractory (RR) cHL could still be cured with salvage chemotherapy and autologous stem-cell transplantation. Brentuximab vedotin (BV) and the anti–PD-1–blocking antibodies, nivolumab and pembrolizumab, are highly effective treatments for cHL and have revolutionized the management of the disease. Recent studies incorporating BV and PD-1 blockade into salvage therapy for RR cHL and into frontline treatment regimens have changed the cHL treatment paradigm. The novel agents are also useful in the treatment of older patients who have poor outcomes with traditional therapy. This manuscript will review current strategies for approaching the management of previously untreated, RR, and challenging populations with cHL, including how to incorporate the novel agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHumansAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalCombined Modality TherapySalvage TherapyTreatment OutcomeImmune Checkpoint InhibitorsDisease ManagementRecurrence

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
  • Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
  • Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

ORCID-Profile: Alex F Herrera

Zitieren

APA

Burton, C., Allen, P., & Herrera, A. F. (2024). Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_433502

Vancouver

Burton C, Allen P, Herrera AF. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease. American Society of Clinical Oncology Educational Book. 2024. doi:10.1200/edbk_433502

BibTeX
@article{Burton2024,
  author = {Burton, Cathy and Allen, Pamela and Herrera, Alex F},
  title = {Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2024},
  doi = {10.1200/edbk_433502}
}
Kostenlos starten →